Erin Currie
Image of Erin Currie

Erin Currie

Senior Associate

Email

erin.currie@aoshearman.com

Phone

+44 20 3088 2446

Offices

London

V-CARD
Erin works on contentious intellectual property matters, with a particular focus on patent litigation in the life sciences sector.

Erin has a BSc in Cell & Molecular Biology and has worked in biomedical research in the areas of neuroscience and cancer in Canada and the UK before becoming a lawyer.

Erin has experience in both innovator/generic and innovator/innovator disputes as well as co-ordination of multi-jurisdictional European litigation. She has worked on patent revocation proceedings relating to a global pharmaceutical and healthcare company blockbuster product, from first instance to the Supreme Court. She has also been involved in some of the major biologics cases over the years.

Expertise

Industries

Published Work

  • United Kingdom - Life Sciences, Getting the Deal Through, 2015
  • Different motile behaviours of human hematopoietic stem versus progenitor cells at the osteoblastic niche, Stem Cell Reports, 2015
  • APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts, PLoS One, 2015
  • CD34(-) cells at the apex of the human hematopoietic stem cell hierarchy have distinctive cellular and molecular signatures, Cell Stem Cell, 2013
  • Multimodal imaging reveals structural and functional heterogeneity in different bone marrow compartments: functional implications on hematopoietic stem cells, Blood, 2013
  • Semaphorin 5B mediates synapse elimination in hippocampal neurons, Neural Development, 2009
  • Undesired effects of a combinatorial treatment for spinal cord injury - transplantation of olfactory ensheathing cells and BDNF infusion to the red nucleus, European Journal of Neuroscience, 2008
Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.